Drug Delivery Business

Dexcom exec highlights benefits of CGM for type 2 diabetes, continued innovation

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.
NBC New York

Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's like

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

Dexcom gives sneak preview of CGM technologies’ long-term health benefits for diabetics

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
Drug Delivery Business

Dexcom highlights breakthrough type 2 diabetes outcomes at ATTD

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.
Nasdaq

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...